Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Possibly—but the headline alone does not identify the company, and an “80% upside” figure is a broker-target comparison, not a promised return. Similar Australian biotech headlines have referred to Clinuvel Pharmaceuticals, Paradigm Biopharmaceuticals and Telix Pharmaceuticals at different times. The relevant company, share price and target need to be checked against the specific article you saw.
Which ASX biotech does the 80% headline mean?
There is no single company that can be identified from the wording “Could this ASX biotech really jump more than 80% in value?” alone. Separate headlines have used similar language for different stocks:
| Company | Reported target and implied upside | What the figure refers to |
|---|---|---|
| Clinuvel Pharmaceuticals (ASX: CUV) | Bell Potter target of A$17.00; 87% implied upside from A$9.10 | Reported by The Motley Fool Australia in May 2026. Both the target and comparison price are historical snapshots, not current figures. |
| Paradigm Biopharmaceuticals (ASX: PAR) | Bell Potter target of A$0.47; more than 80% implied upside | Reported by The Motley Fool Australia in May 2024. The available report does not establish the comparison price here. |
| Telix Pharmaceuticals (ASX: TLX) | JPMorgan target of A$23.60; described as about 80% upside | Reported by The Bull in June 2026. The comparison price is not stated in the available evidence. |
These are reports about three different companies and dates, not competing valuations of one stock. If the headline you saw named a company or linked to an article, use that detail to identify which claim it meant.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →What “80% upside” does—and does not—tell you
Implied upside is a calculation against a particular share price at a particular time. For the reported Clinuvel example, the A$17 target compared with A$9.10 works out to about 87% upside. It does not mean an investor will earn 87%, or that the target will be reached. The share price may have changed since the comparison was made; the target may take time to reach or never be reached; and an investor’s return depends on their own entry price and circumstances.
#1 Best Overall
- High Accuracy and Precision: Each pipette is calibrated in accordance with ISO8655 and each micro pipette is supplied with an individual test certificate.
- Wide Tip Compatibility: It is compatible with most universal tip brands covering full volume range
- Humanization: ergonomic design, lightweight plunger force can reduce repetitive strain injury. The digital display can clearly read the volume setting. Tip ejector for easy and fast needle tip replacement.
- Easy to calibrate: Each pipette is fully calibrated before shipment. It's easy to calibrate for the users with the tools and instruction supplied.
- 1 Year Guarantee and Satisfied Service: we are manufacturer which has more than 20 years experience in the field of lab products. . Any quality problem, we will provide free replacement
A broker target is an estimate based on assumptions, not a forecast guarantee. The reported percentage also does not, by itself, show the probability of success, the potential loss if the thesis fails, or the effect of future share issuance on existing investors. The cited reports do not establish a general success rate for ASX biotech stocks reaching targets that imply 80% upside.
If the headline is about Clinuvel, what is the thesis?
The reported catalyst
The May 2026 Motley Fool Australia report connected Bell Potter’s A$17 target to an anticipated Phase 3 vitiligo trial readout. The report described the investment as speculative. That catalyst may help explain why a broker saw substantial potential, but a clinical milestone is uncertain: an anticipated readout is not the same as a successful result, regulatory approval or commercial sales.
Rank #2
- Durable 304 Stainless Steel Construction: Built from premium 304 stainless steel, this cryogenic box rack provides excellent durability, corrosion resistance, and structural stability. Designed to withstand demanding laboratory environments and long-term ultra-low temperature storage
- Holds Up to 12 Standard 2" Cryo Storage Boxes: The 4-tier rack design holds up to 12 standard 2-inch cryo storage boxes, allowing laboratories to organize cryogenic vials, biological samples, reagents, and research materials efficiently
- Compatible with Ultra-Low Temperature Freezers: Engineered for use in -248 F ultra-low temperature laboratory freezers, providing secure and stable storage for sensitive samples such as vaccines, samples and research specimens.
- Drawer-Style Smooth Access Design: Each layer features a smooth sliding drawer structure, making it easy to access cryogenic boxes without removing the entire rack. Improves workflow efficiency while keeping samples organized and protected
- Maximize Laboratory Freezer Space: The vertical storage design helps optimize freezer storage space, keeping cryogenic boxes neatly organized and easy to locate. Ideal for biotech labs, hospitals, research institutions, universities, and clinical laboratories
A separate, older valuation view
Morningstar analyst Shane Ponraj, CFA, published a Clinuvel analysis on 8 July 2025 that retained an A$18 fair value estimate. The analysis considered Scenesse distribution growth and possible new indications, while identifying uncertainty around diversification, competition and patent coverage. This is an independent valuation view from 2025, with its own assumptions—not confirmation of Bell Potter’s 2026 target or a current company forecast.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problemsThe A$17 Bell Potter target and Morningstar’s A$18 estimate are not directly interchangeable: they were published at different times by different research providers, and the available information does not provide a like-for-like account of their assumptions, time horizons or downside cases.
Rank #3
- Ultra-Low Temperature Performance: An efficient single-stage compressor for the ultra-low temperature freezer enables fast cooling and energy saving. Temperature range from -40℉ to -123℉ provides flexible storage for sensitive lab samples
- Precise ±0.1°C Microcomputer Control: The lab freezer is microprocessor-controlled with an advanced digital interface for real-time monitoring and ultra-precise temperature adjustment, critical for preserving sensitive biological samples
- Customizable Smart Alarm System: Users can set custom temperature thresholds. Audible and visual alarms safeguard critical samples. The ultra low temp freezer includes keyed lock for physical security against unauthorized access
- Space-saving Design: Our 25L lab cryogenic freezer features 28L capacity in a compact upright design (21.7" x 21.7" x 45.1" ) for crowded labs. 304 stainless steel interior withstands daily disinfectants, maintaining cleanliness for sensitive samples
- Wide Applications: Ideal for precise scientific research, long-term sample storage, specialized material testing, and advanced biotech studies, meeting diverse lab needs
What should you verify before treating the number as relevant?
- Company and ticker: establish whether the claim concerns CUV, PAR, TLX or another company.
- Target and date: find the broker’s target and the date it was reported; old targets should not be mistaken for live estimates.
- Comparison price and date: check the share price used to calculate the percentage. A target without its comparison price cannot establish an implied return.
- Catalyst and uncertainty: identify what event or business assumptions underpin the target, and what could prevent them from working.
- Current facts: confirm the live share price, current broker target and latest trial status from up-to-date sources. The figures above do not establish those current facts.
Without those checks, “more than 80%” is best understood as a dated valuation scenario attached to a particular company—not as evidence that an ASX biotech is likely to deliver that return.
Quick Recap
Rank #4
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
